New Retina Radio by Eyetube

When do symptomatic vitreous floaters warrant surgery, and when is observation sufficient? In this episode of New Retina Radio Journal Club with VBS, host Kyle Kovacs, MD, joins Matthew Starr, MD, and Neda Valikodath, MD, to review a major study on vision-degrading myodesopsias from vitreous floaters. They then debate the risks and value of limited refractive vitrectomy for select patients in real-world settings, and review their protocols for patients who present with floaters.

Co-hosts David Fell, MD, and Justin C. Muste, MD, sit down with Allen C. Ho, MD, director of Retina Research at Wills Eye Hospital, and Curtis Heisel, MD, MBA, a vitreoretinal surgery fellow at the University of California San Diego, to discuss the gene therapy landscape in retina. They share their journeys in the space, the therapies under investigation, and how fellows can get involved.

Podcast moderator Lejla Vajzovic, MD, sits down with Robert L. Avery, MD; Carl D. Regillo, MD; and Durga S. Borkar, MD, MMCi, to explore how new therapies hold promise for extending treatment efficacy in patients with wet AMD. They touch on various drug delivery platforms, gene therapy, tyrosine kinase inhibitors, and the challenges of drug development and approval.

Katharine Talcott, MD, and Jorge Fortun, MD, share their approaches to utilizing OCT and other retinal imaging in the clinic and the OR, detailing how OCT plays a role in the workflow of specific patient cases. They emphasize how ZEISS unites diagnostics, data management, and surgery through connectivity. They share real-world case examples for how imaging impacts the day-to-day management of patients and how they treat them.This episode is sponsored by Zeiss.

Are patients with DR at higher risk for TDR, DME, vitreous hemorrhage, or blindness based on race or ethnicity ? Jordan Deaner, MD, moderates a discussion with Vaidehi Dedania, MD, and Rehan Hussain, MD, about a large retrospective cohort study examining more than 627,000 US patients with DR. The panel examines why Black and Hispanic patients faced significantly higher rates of adverse outcomes at  1 and 5 years after diagnosis and unpacks what confounding variables the study could not capture. They consider what these findings should mean for screening strategies, patient education, and the day-to-day management of high-risk diabetic patients in clinic.